Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal.
Department of Medical Oncology, Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal.
JNMA J Nepal Med Assoc. 2022 Jun 1;60(250):569-572. doi: 10.31729/jnma.7400.
Brain metastases in a patient with non-small cell lung cancer carry a grave prognosis. Without effective interventions, the average survival rate is 6 months. Here, we present a case of a 59-year-old male with non-small cell lung cancer and multiple brain metastases treated with radiotherapy followed by bevacizumab maintenance with prolonged survival. There are limited studies establishing the efficiency and toxicity profile of anti-vascular endothelial growth factors for brain metastases. This reported case had a remarkable response with marked clinical and radiological improvement along with a tolerable toxicity profile. Showing the extent of effectiveness and efficacy of anti-vascular endothelial growth factor agents in the case of lung cancer with brain metastases is the main motto of our study.
bevacizumab; brain metastases; radiotherapy.
非小细胞肺癌患者发生脑转移预后极差。如果没有有效的干预措施，平均生存率为 6 个月。在此，我们报告了一例 59 岁男性非小细胞肺癌伴多发脑转移，经放疗联合贝伐单抗维持治疗后，生存时间延长。目前，关于抗血管内皮生长因子治疗脑转移的疗效和毒性特征的研究有限。本报告病例对治疗反应显著，临床和影像学改善明显，且毒性可耐受。本研究的主要目的是探讨抗血管内皮生长因子药物在肺癌伴脑转移患者中的有效性和疗效。
贝伐单抗；脑转移；放疗
